AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06456138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
Study NCT05401591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein shake
Description: Participant will drink a protein shake made using each of the four protein types.
Study NCT05401591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein shake
Description: Participant will drink a protein shake made using each of the four protein types.
Study NCT05200884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
Study NCT05200884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine 4%
Description: The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
Study NCT04796025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab; Bevacizumab Biosimilar
Description: 1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
Study NCT04085042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIVC pack
Description: The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
Study NCT05822648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Description: Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
Study NCT05822648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video Control
Description: We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
Study NCT04340960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Monitoring
Description: Patients in this group will receive home monitoring for NIBP (non-invasive blood pressure), SPO2 (pulse oximetry), and pain scores. These will be monitored 4 times a day for 2 weeks following surgery.
Study NCT05369364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80mg qd po, 6 consecutive weeks
Study NCT05369364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
Study NCT05369364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
Study NCT06069830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 cycles of ESA regimen with sandwiched radiotherapy
Description: Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
Study NCT06069830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
Description: Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
Study NCT06069830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
Description: PD-1 monoclonal antibody, 200mg, i.v. d1
Study NCT04812535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: IFX-1 Monotherapy
Study NCT04812535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1 + pembrolizumab combination therapy
Description: IFX-1 + pembrolizumab combination therapy
Study NCT05074823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.1 mg
Description: Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
Study NCT05074823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.2 mg
Description: will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
Study NCT05074823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.3 mg
Description: will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
Study NCT06255262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: (1) Safety introduction phase (6 cases): 250mg, oral, QD,after one cycle of combined treatment, the occurrence of DLT was evaluated: 1) If ≤1person occurs, continue the dose expansion study at that dose level. 2)In the event of DLT> 1, then the dose of surufatinib was adjusted to 200mg，oral，QD,until disease progression or intolerance of toxicity.~(2) Dose expansion phase (24 cases): RP2D, oral, QD,until disease progression or intolerance of toxicity.
Study NCT06255262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg, Q4W.iv.every 28 days; until disease progression or intolerance of toxicity.
Study NCT05222295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Pulmonary Telerehabilitation
Description: For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
Study NCT05222295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Telerehabilitation
Description: These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
Study NCT00888680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGC20-1531
Description: BGC20-1531 administered orally
Study NCT00888680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: Placebo administered orally
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System
Description: HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis.
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System
Description: HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured.
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System
Description: Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System
Description: EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)
Description: EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)
Description: EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation.
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System
Description: The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
Study NCT05284357 — intervention group
Intervention type: DEVICE
Intervention: Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System
Description: The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
Study NCT05234853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR001
Description: Monoclonal antibody
Study NCT06192667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GC Geanial Injectable (Tokyo,Japan)
Description: Highly filled composite resin
Study NCT06192667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Filtek Z250 Universal Restorative (Germany)
Description: Conventional composite resin
Study NCT04814407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-derived DNA methylation detection
Description: Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
Study NCT05915546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Tablets
Study NCT06524271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented Soybean
Description: Same as described earlier
Study NCT06524271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplement without fermented soybean
Description: Same as described earlier
Study NCT06426498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsonix Bx Pulsar machine tFUS
Description: This is a tFUS device, delivering ultrasound at a dose within the FDA safety guidelines.
Study NCT06198062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin wax bath therapy
Description: this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
Study NCT06198062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin Wax Bath Therapy and Muscle Energy Techniques
Description: This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
Study NCT06305585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primal Reflex Release Technique (PRRT)
Description: Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
Study NCT05608954 — intervention group
Intervention type: OTHER
Intervention: Bobath Concept
Description: Handling of the Bobath Concept
Study NCT05608954 — intervention group
Intervention type: OTHER
Intervention: Pediasuit
Description: Pediasuit
Study NCT05608954 — intervention group
Intervention type: OTHER
Intervention: Locomotor training
Description: Locomotor training
Study NCT05608954 — intervention group
Intervention type: OTHER
Intervention: Stretching
Description: Active, passive, active-assisted stretching
Study NCT05608954 — intervention group
Intervention type: OTHER
Intervention: Psychomotricity
Description: Psychomotor skills
Study NCT05608954 — intervention group
Intervention type: OTHER
Intervention: Virtual reality
Description: Virtual reality
Study NCT06221410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative teaching method: Funny Scenario-Based Education
Description: A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together.
Study NCT06221410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternative teaching method: Mind-mapping Education
Description: As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05706207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0030 injection
Description: 40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
Study NCT05173012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-324
Description: SAGE-324 oral tablets.
Study NCT05173012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAGE-324 Matched Placebo
Description: SAGE-324 matched placebo oral tablets.
Study NCT04645511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon sinuplasty of maxillary sinuses
Description: A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.